Timing of Mirabegron Administration
Mirabegron should be taken once daily, and the FDA label does not specify a particular time of day—it can be taken at any time that is convenient for the patient, with the key being consistency in daily dosing. 111
FDA-Approved Dosing Instructions
The official prescribing information states mirabegron extended-release tablets should be:
- Taken once daily at 25 mg starting dose (can increase to 50 mg after 4-8 weeks)
- Swallowed whole with water (do not chew, divide, or crush)
- Taken with or without food in adults
- Taken with food in pediatric patients 111
The FDA label makes no recommendation about morning versus evening dosing, leaving this decision to patient preference.
Evidence on Timing: Nighttime vs. Daytime Dosing
While the FDA does not mandate a specific time, emerging research suggests timing may matter for certain symptom patterns:
Nighttime dosing (bedtime) may be preferable for patients with:
- Prominent nocturia (nighttime urination)
- Morning urgency episodes (6:00 AM - 12:00 PM)
- Evening urgency episodes (6:00 PM - 12:00 AM)
A 2025 randomized trial found that nighttime dosing significantly improved nocturia episodes at 4 weeks (5.65 to 4.26 episodes, p=0.019) and reduced urgency episodes throughout the day more effectively than daytime dosing 2.
Daytime dosing may be preferable for patients with:
- Coexistent emotional dysfunction related to OAB
- Concerns about remembering bedtime medications
The same trial showed daytime dosing provided greater improvement in emotional quality of life scores (change: -17 vs -6, p=0.006) 2.
Practical Recommendation Algorithm
Choose timing based on predominant symptoms:
- If nocturia is the primary complaint → Take at bedtime
- If daytime urgency/frequency dominates → Take in the morning
- If emotional/quality of life impact is significant → Take in the morning
- If symptoms are evenly distributed → Choose based on patient's routine adherence preference
Important Caveats
- By 12 weeks, both timing strategies showed equivalent efficacy, so the timing advantage appears most relevant in the first 4-8 weeks of treatment 2
- The most critical factor is consistent daily dosing at the same time each day
- Patient adherence trumps optimal timing—choose whatever time the patient will reliably remember
- The extended-release formulation provides 24-hour coverage regardless of timing